AXSM

Axsome Therapeut

• Reuters·6h ago

  Axsome Therapeutics to report first-quarter results, host conference call

• TipRanks·6d ago

  Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

• TipRanks·6d ago

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• TipRanks·6d ago

  Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)

• Benzinga·04/01 17:36

  Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

• Reuters·04/01 16:14

  BUZZ-U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing

• Reuters·04/01 13:14

  BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes

• TipRanks·04/01 12:54

  Axsome acquires global rights to Takeda’s balipodect

• NASDAQ·04/01 11:44

  Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda

• Reuters·04/01 11:40

  BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

• Reuters·04/01 11:27

  BUZZ-Axsome rises as it buys rights to experimental schizophrenia drug

• Benzinga·04/01 11:24

  Axsome Therapeutics Enters Into An Asset Purchase Agreement To Obtain Exclusive Global Rights To TAK-063 (balipodect) From Takeda, Deal Terms Undisclosed

• TipRanks·04/01 11:22

  Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda

• Reuters·04/01 11:07

  Axsome Therapeutics buys global rights to Takeda schizophrenia drug balipodect

• Reuters·04/01 11:02

  Axsome buys global rights to Takeda schizophrenia drug candidate balipodect (TAK-063)